ASCO Annual Meeting: Brain Cancer | Conference

High-Dose Chemo Before RT Results in High Survival in Pediatric Brain Tumors
June 10, 2014

High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.

Armodafinil Fails to Improve Fatigue in Glioma Patients
June 09, 2014

Addition of the drug armodafinil did not improve measures of fatigue in patients with gliomas undergoing treatment with radiotherapy, according to the results of a study presented at the 2014 ASCO Annual Meeting.

Gene Signature Can Predict 3-Year Glioma Survival
June 05, 2014

Researchers identified a six-gene signature that can help to predict the 3-year survival outcome for patients with grade II or grade III gliomas, independent of the patient’s histology, grade, and IDH1 mutations status.

Dendritic Cell Vaccine Improved PFS, Not OS in Glioblastoma
June 01, 2014

A phase II trial evaluating the use of a dendritic cell vaccine, ICT-107, has shown that the immunotherapy had a positive effect on progression-free survival in patients with glioblastoma.

FLT-PET Fails to Distinguish True Glioblastoma Progression
May 31, 2014

Positron emission tomography using [18]F-fluorothymidine as a tracer failed to distinguish true progression of glioblastoma from pseudoprogression in a small single-center study presented at the 2014 ASCO Annual Meeting.

ASCO: Molecular Diagnostics Allow Further Understanding of Medulloblastoma
May 28, 2014

As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss how molecular diagnosis in medulloblastoma affects clinical decision-making.